medigraphic.com
ISSN 1561-2937 (Impreso)

2019, Número 4

<< Anterior Siguiente >>

Rev Cubana Cardiol Cir Cardiovasc 2019; 25 (4)


Enfermedad aterosclerótica subclínica

Valdés MA, Naranjo DA

Idioma: Español
Referencias bibliográficas: 56
Paginas:
Archivo PDF: 250.40 Kb.


RESUMEN

La historia natural de la enfermedad aterosclerótica comprende un largo período silente o asintomático. Esa condición, llamada enfermedad aterosclerosis subclínica (EAS), es altamente prevalente en la población adulta en general y se ha asociado a la morbimortalidad cardiovascular. Los marcadores de EAS son un conjunto de hallazgos anatómicos, funcionales o serológicos que permiten diagnosticar la existencia de la enfermedad aterosclerótica en la etapa preclínica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rizo Rivera GO, Ramírez Gómez JI, Gómez Jarcia YC. Enfoque actual sobre la fisiopatología del síndrome coronario agudo. Rev Cub de Med. 2009; 48(3): 71- 87.

  2. Organización Mundial de la salud. Enfermedades cardiovasculares. [Página en la internet] 2009. [citado 2010 Enero 03]. Disponible en: http://www.who.int/mediacentre/factsheats/f5317/es/index.html.

  3. Ford ES, Greenlund KJ, Hong Y. Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States.Circulation. 2012; 125 (8):987-95.

  4. Gutiérrez A. La aterosclerosis como desencadenante de la patología cardiovascular. Rev Facultad de Ciencias de la Salud. 2010; 7: 5-7.

  5. Fernández-Britto JE. La lesión aterosclerótica: Estado del arte a las puertas del siglo XXI. Rev Cubana InvestBiomed 1998; 17(2):112-27.

  6. Pedro Patritti J, Deferrari A, Patritti Isasi JJ. Diagnóstico no invasivo de la aterosclerosis subclínica. Riesgo cardiovascular.Arch. Med Int.2009;31(1):1-10

  7. Bozzo RA, Rey R, Manente D, Rostan M, Vitagliano L, Villami A. Valor de la aterosclerosis subclínica en la determinación del riesgo cardiovascular. Rev Argent Cardiol 2016; 84:215-221.

  8. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010; 55:16007.

  9. Prati P, Tosetto A, Vanuzzo D, Bader G, Casaroli M, Canciani L et al. Carotid intima media thickness and plaques can predict the occurrence of ischemic cerebrovascular events. Stroke 2008; 39:24706.

  10. Oliveira Garcia MM, Galeffi Rodrigues M, Dos Reis Neto JA, Claudio Correia L. Influencia de la Aterosclerosis Subclínica en la función diastólica en Individuos sin enfermedad Cardiovascular Arq Bras Cardiol 2010; 95(4): 473-479.

  11. Aboyans V, Criqui M, Abraham P, Allison M, Creager M, Diehm C. Measurement and interpretation of the anklebrachial index. A Scientific Statement from the American Heart Association. Circulation. 2012; 126:2890-2909.

  12. Doobay A, Anand S. Sensitivity and specificity of the ankle brachial index to predict future cardiovascular outcomes: A systematic review. Arterioscler Thromb Vasc Biol. 2005; 25; 1463-1469.

  13. Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation. 2004; 109:3112-3121.

  14. McDermott MM, Liu K, Criqui MH, Ruth K, Goff D, Saad MF et al. Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2005; 162(1):33–41.

  15. Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2000; 86(6):615–8.

  16. Kajikawa M, Maruhashi T, Iwamoto Y, et al. Borderline Ankle-Brachial Index Value of 0.91-0.99 Is Associated With Endothelial Dysfunction. Circ J. 2014; 78(7):1740–5.

  17. Tanaka S, Kaneko H, Kano H, Matsuno S, Suzuki S, Takai H et al. The predictive value of the borderline ankle-brachial index for long-term clinical outcomes: An observational cohort study. Atherosclerosis. 2016; 250:69–76.

  18. Fowkes FGR, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008; 300:197208.

  19. Collins TC, Slovut DP, Newton R Jr, Johnson WD, Larrivee S, Patterson J et al. Ideal cardiovascular health and peripheral artery disease in African Americans: Results from the Jackson Heart Study. Prev Med Rep. 2017; 7: 20–5.

  20. Arrebola-Moreno AL, Lacaustra M, Kaski LC. Evaluación no invasiva de la función endotelial en la práctica clínica. Rev Esp Cardiol. 2012; 65(1):80-90.

  21. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilatation of the brachial artery: a report of the international Brachial Artery Reactivity Task Force. J Am Coll Cardiol.2002; 39:257-265.

  22. Castellano Vazqueza JM. De las escalas de riesgo poblacional a la cuantificación de la ateroesclerosis subclínica: hacia un nuevo paradigma en la predicción cardiovascular. Rev Esp Cardiol. 2017; 70(7):532–534.

  23. Touboul P, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23(1):75-80.

  24. Naqvi TZ, Lee M-S. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging.2014; 7:1025-1038.

  25. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.38

  26. Hobbs FD. Cardiovascular disease: different strategies for primary and secondary prevention? Heart. 2004; 90(10):1217–23.

  27. Force USPST, Bibbins-Domingo K, Grossman DC, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 316(19): 1997–2007.

  28. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2935–2959.

  29. Task FM, Piepoli MF, Hoes AW, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016; 252:207.

  30. Peters SA, Den Ruijter HM, Bots ML, et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart. 2012; 98:177–184.

  31. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012; 220:128–33.

  32. Budoff MJ, Gul KM. Expert review on coronary calcium. Vasc Health Risk Manag.2008; 4:315-324.

  33. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15:827-832.

  34. Detrano R, Hsiai T, Wang S, Puentes G, Fallavollita J, Shields P, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol. 1996; 27:285-290.

  35. Pasterkamp G, Schoneveld AH, Hillen B, Banga JD, Haudenschild CC, Borst C et al. Is plaque formation in the common carotid artery representative for plaque formation and luminal stenosis in other atherosclerotic peripheral arteries? A post mortem study. Atherosclerosis 1998; 137:205–10.

  36. Fernández-Ortiz A, Jiménez-Borreguero LJ, Peñalvo JL, Ordovás JM, Mocoroa A, Fernández-Friera L et al. The Progression and Early Detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am Heart J. 2013; 166:990–998.

  37. Laclaustra M, Casasnovas J A, Fernández-Ortiz A, Fuster V, León-Latre M, Jiménez-Borreguero LJ et al. Femoral and Carotid Subclinical Atherosclerosis Association with Risk Factors and Coronary Calcium. JACC.2016;67 (11) :1 2 6 3 – 7 4

  38. Moon SH, Cho YS, Noh TS, Choi JY, Kim BT, Lee KH. Carotid FDG uptake improves prediction of future cardiovascular events in asymptomatic individuals. J Am Coll Cardiol Img 2015; 8:949–56.

  39. Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. J Am Coll Cardiol Img 2013; 6:1250–9.

  40. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009; 50:1611–20.

  41. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001; 26:314–9.

  42. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 2001; 89:305316.

  43. Fayad ZA, Fuster V, Nikolaou K, Becker C. Computed tomography and magnetic resonance imaging for non-invasive coronary angiography and plaque imaging: current and potential future concepts. Circulation. 2002; 106: 2026-2034.

  44. Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque haemorrhage in advanced human carotid plaques. Circulation. 2001; 104:2051-2056.

  45. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/ magnetic resonance imaging. J Am Coll Cardiol.2005;46:1209-1218

  46. Von Schulthess GK, Kuhn FP, Kaufmann P, Veit-Haibach P. Clinical positron emission tomography/magnetic resonance imaging applications. Semin Nucl Med 2013; 43:3–10.

  47. Ripa RS, Knudsen A, Hag AM, Lebech AM, Loft A, Keller SH, et al. Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. AmJ Nucl Med Mol Imaging 2013; 3:361–71.

  48. Hyafil F1, Schindler A, Sepp D, Obenhuber T, Bayer-Karpinska A, Boeckh-Behrens T et al. High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined F-FDG PET/MR imaging. Eur J Nucl Med Mol Imaging 2016; 43:270–9.

  49. Bini J, Robson PM, Calcagno C, Eldib M, Fayad ZA. Quantitative carotid PET/MR imaging: clinical evaluation of MR-Attenuation correction versus CT-Attenuation correction in (18) F-FDGPET/MR emission data and comparison to PET/CT. Am J Nucl Med Mol Imaging 2015; 5:293–304.

  50. Lawes CMM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001.Lancet. 2008;371:1513-1518

  51. Karim R, Hodis HN, Detrano R, Liu C, Liu C, Mack WJ. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008; 102:825-83.

  52. Urbina EM, Kieltkya L, Tsai J, Srinivasan SR, Berenson GS. Impact of multiple cardiovascular risk factors on brachial artery distensibility in young adults: the Bogalusa Heart Study. Am J Hypertens. 2005; 18:767-771.

  53. Mattace-Raso FUS, van der Cammen TJM, Hofman A, van Popele NM, Bos ML, Schalekamp MADH, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006; 113:657-663.

  54. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001; 103:987-992.

  55. Sillesen H, Muntendam P, Adourian A, Entrekin R, Garcia M et al. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging.2012; 5:681–689.

  56. Baber U, Mehran R, Sartori S, Schoos MM, Sillesen H, Muntendam P et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study.JAmCollCardiol.2015; 65:1065–107




2020     |     www.medigraphic.com